Role of individual gamma-carboxyglutamic acid residues of activated human protein C in defining its in vitro anticoagulant activity.

To evaluate the contributions of individual gamma-carboxyglutamic acid (gla) residues to the overall Ca(2+)-dependent anticoagulant activity of activated human protein C (APC), we used recombinant (r) DNA technology to generate protein C (PC) variants in which each of the gla precursor glutamic acid (E) residues (positions 6, 7, 14, 16, 19, 20, 25, 26, and 29) was separately altered to aspartic acid (D). In one case, a gla26V mutation ([gla26V]r-PC) was constructed because a patient with this particular substitution in coagulation factor IX had been previously identified. Two additional r-PC mutants were generated, viz, an r-PC variant containing a substitution at arginine (R) 15 ([R15]r-PC), because this particular R residue is conserved in all gla-containing blood coagulation proteins, as well as a variant r-PC with substitution of an E at position 32 ([F31L, Q32E]r-PC), because gla residues are found in other proteins at this sequence location. This latter protein did undergo gamma-carboxylation at the newly inserted E32 position. For each of the 11 recombinant variants, a subpopulation of PC molecules that were gamma-carboxylated at all nonmutated gla-precursor E residues has been purified by anion exchange chromatography and, where necessary, affinity chromatography on an antihuman PC column. The r-PC muteins were converted to their respective r-APC forms and assayed for their amidolytic activities and Ca(2+)-dependent anticoagulant properties. While no significant differences were found between wild-type (wt) r-APC and r-APC mutants in the amidolytic assays, lack of a single gla residue at any of the following locations, viz, 7, 16, 20, or 26, led to virtual complete disappearance of the Ca(2+)-dependent anticoagulant activity of the relevant r-APC mutant, as compared with its wt counterpart. On the other hand, single eliminations of any of the gla residues located at positions 6, 14, or 19 of r-APC resulted in variant recombinant molecules with substantial anticoagulant activity (80% to 92%), relative to wtr-APC. Mutation of gla residues at positions 25 and 29 resulted in r-APC variants with significant but low (24% and 9% of wtr-APC, respectively) levels of anticoagulant activity. The variant, [R15L]r-APC, possessed only 19% of the anticoagulant activity of wrt-APC, while inclusion of gla at position 32 in the variant, [F31L, Q32gla]r-APC, resulted in a recombinant enzyme with an anticoagulant activity equivalent to that of wtr-APC.

[1]  F. Castellino,et al.  Synthesis, purification, and properties of a peptide that enhances the activation of human [Glu1]plasminogen by tissue plasminogen activator and retards fibrin polymerization. , 2009, International journal of peptide and protein research.

[2]  A. D. de Vos,et al.  The Ca2+ ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1. , 1994, Biochemistry.

[3]  P. Reitsma,et al.  The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. , 1991, Blood.

[4]  F. Castellino,et al.  Role of the hexapeptide disulfide loop present in the gamma-carboxyglutamic acid domain of human protein C in its activation properties and in the in vitro anticoagulant activity of activated protein C. , 1991, Biochemistry.

[5]  F. Walker,et al.  Species specificity of the fibrinolytic effects of activated protein C. , 1991, Thrombosis research.

[6]  J. Walls,et al.  Glycosylation of human protein C affects its secretion, processing, functional activities, and activation by thrombin. , 1991, The Journal of biological chemistry.

[7]  H. Saito,et al.  Three Distinct Point Mutations in the Factor IX Gene of Three Japanese CRM+ Hemophilia B Patients (Factor IX BMNagoya 2, Factor IX Nagoya 3 and 4) , 1991, Thrombosis and Haemostasis.

[8]  F. Castellino,et al.  A gamma-carboxyglutamic acid (gamma) variant (gamma 6D, gamma 7D) of human activated protein C displays greatly reduced activity as an anticoagulant. , 1990, Biochemistry.

[9]  C. Walsh,et al.  Identification of amino acids in the gamma-carboxylation recognition site on the propeptide of prothrombin. , 1990, Journal of Biological Chemistry.

[10]  D. Mcclure,et al.  Characterization and Novel Purification of Recombinant Human Protein C from Three Mammalian Cell Lines , 1990, Bio/Technology.

[11]  A. Thompson,et al.  Factor IX Chongqing: a New Mutation in the Calcium-Binding Domain of Factor IX Resulting in Severe Hemophilia B , 1990, Thrombosis and Haemostasis.

[12]  K. Mann,et al.  Evidence for a common metal ion-dependent transition in the 4-carboxyglutamic acid domains of several vitamin K-dependent proteins. , 1989, The Journal of biological chemistry.

[13]  J. Buerstedde,et al.  Functionally important regions of the factor IX gene have a low rate of polymorphism and a high rate of mutation in the dinucleotide CpG. , 1989, American journal of human genetics.

[14]  H. Ehrlich,et al.  Direct expression of recombinant activated human protein C, a serine protease. , 1989, The Journal of biological chemistry.

[15]  B. Furie,et al.  Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties. , 1989, The Journal of biological chemistry.

[16]  A. Thompson,et al.  Three point mutations in the factor IX genes of five hemophilia B patients. Identification strategy using localization by altered epitopes in their hemophilic proteins. , 1989, The Journal of clinical investigation.

[17]  B. Lämmle,et al.  Immunoblotting studies of the molecular forms of protein C in plasma. , 1988, Thrombosis research.

[18]  C. Orthner,et al.  PURIFICATION AND CHARACTERIZATION OF A PROTEIN C ACTIVATOR FROM THE VENOM OF AGKISTRODON CONTORTRIX CONTORTRIX , 1988, Thrombosis and Haemostasis.

[19]  J. Griffin,et al.  The Frequency of Type I Heterozygous Protein S and Protein C Deficiency in 141 Unrelated Young Patients with Venous Thrombosis , 1988, Thrombosis and Haemostasis.

[20]  B. Grinnell,et al.  Trans–Activated Expression of Fully Gamma–Carboxylated Recombinant Human Protein C, an Antithrombotic Factor , 1987, Bio/Technology.

[21]  B. Coller,et al.  Deficiency of Plasma Protein S, Protein C, or Antithrombin III and Arterial Thrombosis , 1987, Arteriosclerosis.

[22]  A. Cantor,et al.  Recognition site directing vitamin K-dependent γ-carboxylation resides on the propeptide of factor IX , 1987, Cell.

[23]  J. Griffin,et al.  Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. , 1986, Blood.

[24]  B. Furie,et al.  Distribution of gamma-carboxyglutamic acid residues in partially carboxylated human prothrombins. , 1986, The Journal of biological chemistry.

[25]  M. Howden,et al.  Detection of specific proenzyme activators in snake venoms by a new immunoabsorbant-chromogenic substrate method. , 1985, Biochimica et biophysica acta.

[26]  G. Crabtree,et al.  The structure and evolution of a 461 amino acid human protein C precursor and its messenger RNA, based upon the DNA sequence of cloned human liver cDNAs. , 1985, Nucleic acids research.

[27]  E. Davie,et al.  The nucleotide sequence of the gene for human protein C. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. Davie,et al.  Characterization of a cDNA coding for human protein C. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[29]  K. Kurachi,et al.  Characterization of a cDNA coding for human factor VII. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. MacGillivray,et al.  Characterization of the complementary deoxyribonucleic acid and gene coding for human prothrombin. , 1983, Biochemistry.

[31]  P. Fernlund,et al.  beta-Hydroxyaspartic acid in vitamin K-dependent protein C. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[32]  K. Kurachi,et al.  Isolation and characterization of a cDNA coding for human factor IX. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Esmon,et al.  Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. , 1982, The Journal of biological chemistry.

[34]  C. Esmon,et al.  Generation of fibrinolytic activity by infusion of activated protein C into dogs. , 1981, The Journal of clinical investigation.

[35]  K. Katayama,et al.  A high-performance liquid chromatographic method for the simultaneous determination of gamma-carboxyglutamic acid and glutamic acid in proteins, bone, and urine. , 1981, Analytical biochemistry.

[36]  W. Kisiel,et al.  Interaction of calcium with bovine plasma protein C. , 1981, Biochemistry.

[37]  F. Walker.  Regulation of activated protein C by a new protein. A possible function for bovine protein S. , 1980, The Journal of biological chemistry.

[38]  E. Davie,et al.  Preparation and properties of bovine factor VIII (antihemophilic factor). , 1980, Biochemistry.

[39]  W. Kisiel,et al.  Anticoagulant properties of bovine plasma protein C following activation by thrombin. , 1977, Biochemistry.

[40]  K. Mann,et al.  Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. , 1988, Annual review of biochemistry.

[41]  V. V. van Hinsbergh,et al.  The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro. , 1986, Blood.

[42]  F. Taylor,et al.  A new function for activated protein C: activated protein C prevents inhibition of plasminogen activators by releasate from mononuclear leukocytes--platelet suspensions stimulated by phorbol diester. , 1985, Thrombosis research.

[43]  K. Kurachi,et al.  Characterization of a cDNA coding for human factor X. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[44]  W. Kisiel.  Human plasma protein C: isolation, characterization, and mechanism of activation by alpha-thrombin. , 1979, The Journal of clinical investigation.

[45]  U. K. Laemmli,et al.  Cleavage of structural proteins during , 1970 .

[46]  P. Price,et al.  Molecular cloning of matrix Gla protein : Implications for substrate recognition by the vitamin K-dependent y-carboxylase ( r-carboxyglutamic acid / bone / protein carboxylation ) , 2022 .